Cyberknife Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The CyberKnife market covers robotic stereotactic radiosurgery equipment used to deliver precisely targeted radiation therapy to tumors and vascular malformations without surgical incisions. The global market was valued at approximately $0.72 billion in 2025 and is forecast to expand significantly over the coming decade as healthcare systems adopt minimally invasive treatment options. North America currently leads adoption, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high prevalence of lifestyle-related cancers requiring precise intervention.

• •Market valued at approximately $0.72 billion USD in 2025
• •Technology enables non-invasive treatment of tumors and vascular malformations with sub-millimeter precision
• •Primary applications include lung, brain, liver, and pancreatic cancer treatments

The rising global incidence of cancer, particularly lung and prostate cancers in aging populations, directly fuels demand for precise radiation treatment options that can target tumors while preserving healthy tissue. Technological advancements in image-guided radiotherapy and robotic positioning systems have improved treatment accuracy and reduced procedure times, making CyberKnife systems more accessible to broader patient populations. Additionally, growing preference for outpatient procedures over lengthy hospital stays, combined with expanding insurance coverage for stereotactic treatments, creates favorable economic conditions for market expansion.

• •Increasing global cancer prevalence driving demand for precise, non-invasive treatment modalities
• •Advancements in image-guided robotics and real-time tracking improving treatment accuracy and safety
• •Favorable reimbursement policies and shift toward outpatient care reducing treatment costs

The market segments primarily by application, with tumor and cancer treatment (including lung, brain, liver, and pancreatic cancers) representing the dominant category, alongside vascular malformation treatments. End-use categories include hospitals, outpatient facilities, and research and manufacturing operations, with hospitals maintaining the largest share due to their comprehensive oncology capabilities. Geographically, North America commands the largest market share, followed by Europe and the Asia-Pacific region, where increasing healthcare investments and rising cancer awareness are accelerating adoption rates across emerging economies.

• •Applications span lung, brain, liver, and pancreatic cancers plus vascular malformations
• •Hospitals represent the primary end-use segment, with growing outpatient facility adoption
• •North America leads regionally, with Asia-Pacific showing the fastest growth trajectory

What are the recent trends and outlook?

The market outlook through 2032 remains strongly positive as artificial intelligence integration enhances treatment planning and adaptive radiotherapy capabilities. Miniaturization of components and reduced system costs are expected to expand adoption in mid-sized hospitals and regional cancer centers previously unable to justify capital expenditure. Furthermore, the development of new clinical indications and combination therapies incorporating immunotherapy are likely to broaden the addressable patient population and sustain the projected 16.5% compound annual growth rate throughout the forecast period.

• •AI-powered treatment planning and adaptive radiotherapy improving clinical precision
• •Cost reduction and system miniaturization enabling broader hospital adoption
• •Expanding clinical indications and combination therapies supporting sustained market growth